ZAO «Binnopharm»

General activity of CJSC «Binnopharm» is pharmaceutical production: development and production of biotechnological genetically engineered medical products, including Hepatitis B vaccines; production and wholesale turnover of medical products and pharmaceutical substances; assets capitalization in pharmaceutical field (acquisition of companies specialized in developing, producing and selling medical products).
100% of its charter capital is a property of JSFC Sistema. JSFC Sistema invested more than 4.3 bln RUR in manufacturing complex.

- see us on Twitter

Company news

07/05/11

International Pharmaceutical and Biotechnologies Forum IPhEB took place in St. Petersburg for the first time. The new discussion place welcomed both business players and authorities.

05/04/11

MOSCOW, April 5 (Reuters) - Belgian drugmaker UCB will sign an agreement on Tuesday with Russia's Sistema's unit Binnopharm for local packaging and production, to boost its presence on the rapidly growing Russian market.

News archive RSS

Press-releases

03/02/11

Sistema (the “Group”) (LSE: SSA), the largest diversified public financial corporation in Russia and the CIS, which invests in and is a major shareholder of companies operating in different industries, today announced the appointment of Igor Varlamov as General Director of CJSC Binnopharm, a subsidiary of Sistema. Mr. Varlamov previously held the position of General Director of Alliance Healthcare Russia, one of the largest pharmacy chains in Russia.

26/11/10

GlaxoSmithKline (GSK) and JSC Binnopharm (Binnopharm) today announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia. The agreement was signed in Moscow during the session of the Russian-British Intergovernmental Steering Committee (ISC) for Trade and Investment.

All press-releases